Technical Analysis for HRMY - Harmony Biosciences Holdings, Inc.

Grade Last Price % Change Price Change
B 38.78 -1.47% -0.58
HRMY closed down 1.47 percent on Thursday, February 6, 2025, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 20
*** please verify all earnings dates ***
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
NR7 Range Contraction -1.47%
NR7-2 Range Contraction -1.47%
MACD Bearish Signal Line Cross Bearish -0.51%
NR7 Range Contraction -0.51%
Gapped Down Weakness 0.21%
NR7 Range Contraction -1.92%
Up 3 Days in a Row Strength -1.92%
Up 4 Days in a Row Strength -1.92%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 10 hours ago
Fell Below 10 DMA about 10 hours ago
Possible NR7 about 10 hours ago
60 Minute Opening Range Breakdown about 11 hours ago
Fell Below Previous Day's Low about 11 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Neurological Disorders Stage Pharmaceutical Ethers Urological Disorders Chloroarenes Narcolepsy Piperidines Rare Neurological Disorders Stimulants

Is HRMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 41.61
52 Week Low 28.14
Average Volume 539,604
200-Day Moving Average 33.92
50-Day Moving Average 35.66
20-Day Moving Average 38.03
10-Day Moving Average 38.76
Average True Range 1.37
RSI (14) 58.68
ADX 24.32
+DI 27.42
-DI 18.47
Chandelier Exit (Long, 3 ATRs) 36.83
Chandelier Exit (Short, 3 ATRs) 37.26
Upper Bollinger Bands 41.22
Lower Bollinger Band 34.84
Percent B (%b) 0.62
BandWidth 16.78
MACD Line 1.04
MACD Signal Line 1.10
MACD Histogram -0.0573
Fundamentals Value
Market Cap 2.21 Billion
Num Shares 57 Million
EPS 2.14
Price-to-Earnings (P/E) Ratio 18.12
Price-to-Sales 3.27
Price-to-Book 3.68
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.19
Resistance 3 (R3) 40.30 39.93 39.96
Resistance 2 (R2) 39.93 39.57 39.88 39.88
Resistance 1 (R1) 39.36 39.35 39.18 39.25 39.80
Pivot Point 38.99 38.99 38.90 38.94 38.99
Support 1 (S1) 38.42 38.63 38.24 38.31 37.76
Support 2 (S2) 38.05 38.41 38.00 37.68
Support 3 (S3) 37.48 38.05 37.61
Support 4 (S4) 37.37